NanoSyrinxNanoSyrinx is a discovery stage synthetic biology company, creating a next-generation platform technology for the targeted intracellular delivery of biological medicines. Most drugs do not traverse the body well and they often end up in places where they are not intended to act, limiting their effectiveness and leading to unwanted side-effects. This is an even greater problem for biologic drugs, such as antibodies and peptides; and consequently new delivery modalities are sorely needed.
We are on a mission to fundamentally revolutionise how medicines are administered – on a nanoscopic scale.
Building on over a decade of fundamental research, our scientists are harnessing the unique properties of Nature’s own elegant solution to the intracellular bioavailability problem.
“NanoSyrinx’s founding team completed ICURe in 2017. Following conversations with >100 stakeholders from the biotech, pharmaceutical and VC investment community, it was clear that there was a significant market opportunity for new technologies, which could deliver biological drugs selectively to the interior of cells. It was also clear that further technical validation and IP protection was needed, before the opportunity was “investable”. Using the market feedback from ICURe, the team were able to secure >£300k of proof of concept funding from the BBSRC and the University of Warwick, to generate more data and secure the IP. Additional support was provided by Warwick Innovations to enable the team to attend industry and investor partnering events.
In 2020, the company secured pre-seed investment of £400k led by M Ventures, matched by a £200k grant from Innovate UK.
Following the successful completion of initial milestones, the company completed an oversubscribed Seed round, totaling just over £6.2m in 2021, co-led by Octopus Ventures and M Venture”
Dr James Lapworth, Chief Business Officer
Told to go back to the lab because technical validation was not strong enough and no IP protection was in place
Secured Warwick POC funding £69k, secured BBRSC Pathfinder award £14k
Secured BBSRC Follow-on Fund grant £250k, IP filed
Spin out company formed
Secured initial investment £400k led by M Ventures, secured £200k Innovate UK Grant, work though pandemic to top-up IP
Secured Seed Investment £6.2m co-led by Octopus Ventures and M Ventures
What companies had to say about the ICURe programme?
Our technology has the potential to overcome many of the issues by delivering biological medicines directly into cells in a targeted manner.
Over the coming months, we will be working with partners to deliver an ambitious R&D program which will demonstrate the feasibility of our technology in a range of therapeutic areas. We fully intend to be a part of the solution, with the help of the ICURe programme.
Dr Joe Healey
CEO & Founder
Our long term vision is to develop new medicines which leverage the unique capabilities of our nanosyringe platform technology.
In the era of proteomics and genomics, a huge number of new drug targets are being identified, which have the potential to improve the lives of millions of people, with currently unmet medical needs.
The problem is that the majority of these targets are inside the cell and they cannot be accessed using currently available delivery approaches.